Boehringer and Ablynx Sign US$265 M Deal for Use of Nanobodies® in Alzheimer’s Disease
By Business Review Editor
Pharma Deals Review: Vol 2007 Issue 80 (Table of Contents)
Published: 7 Feb-2007
DOI: 10.3833/pdr.v2007.i80.391 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Boehringer Ingelheim and Ablynx entered into an exclusive worldwide collaboration and license agreement worth almost US$265 M to discover and develop new therapies for Alzheimer’s disease using Ablynx’s Nanobodies® a novel class of antibody-derived therapeutic proteins...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS